Clinical Trial Update: Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER [Phase 2]

View source ↗

Summary

A Phase II open-label trial (NICER) is evaluating neoadjuvant immunochemotherapy for resectable non-metastatic colon cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Snippet

Sponsor: Baylor College of Medicine | Conditions: Stage I Colon Cancer, Stage II Colon Cancer | Phase 2 | Status: RECRUITING